Prospective Randomized Comparative Study of Myeloablative Fludarabine/Busulfan (Flu/Bu4) and Fludarabine/Busulfan/Total Body Irradiation (Flu/Bu4/TBI) Conditioning Regimen for Patients with Myeloid Diseases
Hyung C. Suh(Science Applications International Corporation (United States)), Michèle L. Donato(The University of Texas Health Science Center at Houston), David H. Vesole(Hackensack University Medical Center), Phyllis McKiernan(Hackensack University Medical Center), Alan P Skarbnik(Novant Health), Themba Nyirenda(Hackensack University Medical Center), Scott D. Rowley(Johns Hopkins Hospital), M.S. Baker(Hackensack University Medical Center), Mary E Dilorenzo(Novant Health), Sukhdeep Kaur(Hackensack University Medical Center), Michele Boonstra(Hackensack University Medical Center), Brittany Lukasik(Hackensack University Medical Center)
Cited by 0
Related Papers
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
|Journal of Clinical Oncology|1998|927